End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
114.1 CNY | -1.75% | -7.79% | -9.38% |
Apr. 22 | Anhui Huaheng Biotechnology's Q1 Profit Jumps 7% | MT |
Apr. 22 | Anhui Huaheng Biotechnology's 2023 Profit Jumps 40% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The firm trades with high earnings multiples: 28.39 times its 2024 earnings per share.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.38% | 2.48B | - | ||
-1.19% | 28.85B | B- | ||
+20.82% | 24.98B | B | ||
+4.67% | 11.04B | B- | ||
+15.73% | 5.3B | C- | ||
+17.59% | 4.44B | B+ | ||
-8.90% | 3.81B | C | ||
+2.33% | 3.38B | B+ | ||
+0.07% | 2.99B | C+ | ||
+25.54% | 2.78B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688639 Stock
- Ratings Anhui Huaheng Biotechnology Co., Ltd.